|
Synonyms: CK-301 | CK301 | cosibelimab-ipdl | Unloxcyt®
cosibelimab is an approved drug (FDA (2024))
Compound class:
Antibody
Comment: Cosibelimab (CK-301) is a human anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibody. It belongs to the immune checkpoint inhibitor class of anti-tumour drugs. Cosibelimab blocks inhibitory PD-L1 regulation of the anti-tumour immune response and induces antibody-dependent cell-mediated cytotoxicity (ADCC).
Peptide sequence alignments indicate identity between peptide sequences for the INN cosibelimab and those for antibody CTI-48 as claimed in patent US10590199B2 [1]. |
| No information available. |
Summary of Clinical Use  |
| The FDA approved cosibelimab in December 2024, to treat metastatic/locally advanced cutaneous squamous cell carcinoma. At the time of approval, cosibelimab was the first and only anti-PD-L1 therapeutic authorised for use in this indication. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Phase 1 Interventional | Checkpoint Therapeutics, Inc. | 2 | |
